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MaRadiation-associated cardiac disease, a heterogeneous and complex disease, manifests years or even decades following
radiation exposure to the chest. It is associated with a significantly higher morbidity and mortality. Often, the presen-
tation is vague and overlaps with many diseases, presenting unique diagnostic and management issues. As a result, a high
index of suspicion followed by multimodality imaging is crucial, along with comprehensive screening to enable early
detection. Timing of intervention should be carefully considered in these patients, because surgery is often complex with
an emerging role of percutaneous interventions. (J Am Coll Cardiol 2019;74:905–27) © 2019 by the American College of
Cardiology Foundation.R adiotherapy (XRT) is frequently used as anadjunct to surgery/chemotherapy in thoracicmalignancies and lymphomas. Although
XRT results in significantly improved survival of can-
cer patients, the irradiation of healthy surrounding
tissues results in long-term side effects. Radiation-
associated cardiac disease (RACD) and radiation-
associated pulmonary disease (RAPD) can develop
immediately or gradually, often several years
following XRT. Although modern XRT delivery tech-
niques have significantly reduced the dose and car-
diac involvement, a major issue remains: the
development of RACD decades following high-dose
XRT. Also, clinicians often do not associate XRT expo-
sure in the distant past with current cardiac manifes-
tations (which range from pericarditis, coronary
artery disease [CAD], valvular heart disease, noni-
schemic cardiomyopathy, and conduction abnormal-
ities) (Central Illustration). Unfortunately, the presenting
picture may be clouded by the contribution of
shared common risk factors of cardiovascular disease,
making precise diagnosis difficult. This document
represents a consensus effort by a broad range of
experts to provide a focused overview of RACD,. Desai has received support from the Haslam Family endowed chair in c
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PREVALENCE AND RISK FACTORS
Despite data from many large observational studies,
the exact prevalence of RACD is difficult to determine
because of heterogeneity of presentation, under-
recognition of manifested disease and improvement
of XRT delivery techniques over the years. Most
studies report prevalence based on XRT exposure
from decades ago; and the prevalence using modern
XRT protocols is still poorly defined and would take
years to determine. As shown in Table 1, there are
varying degrees of data related to prevalence of
various manifestations of RACD and RAPD (1–14),
with most of the data reported from XRT for treat-
ment of breast cancer and Hodgkin’s lymphoma
decades ago. However, on the basis of available data,
mediastinal XRT is associated with significantly
increased risk of heart failure with predominantly
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AB BR E V I A T I O N S
AND ACRONYM S
AS = aortic stenosis
AVR = aortic valve
replacement
BMS = bare-metal stent
CAD = coronary artery disease
CMR = cardiac magnetic
resonance
CT = computed tomography
DIBH = deep inspiratory breath
hold
GLS = global longitudinal
strain
IMN = internal mammary node
IMN-RT = internal mammary
node radiotherapy
LV = left ventricle/ventricular














 RACD, a heterogeneous disease that can
manifest years or decades following ra-
diation exposure to the chest, is associ-
ated with high morbidity and mortality
 It is crucial to develop comprehensive
multimodality imaging-based screening
protocols to adequately identify those at
risk, plan interventions, and evaluate
treatment responses.
 Coordinated management by an experi-
enced team of providers at a center of
excellence is strongly advocated with
individualized timing of surgery or
percutaneous interventions.
 The longer-term goal should involve
developing radiotherapy protocols that
minimize the chances of developing
RACD.
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907valvular heart disease, electrical abnormalities
(including autonomic dysfunction), pericardial dis-
ease, and porcelain aorta. Table 2 lists the potential
risk factors for RACD.
EVOLUTION OF RADIOTHERAPY
The guiding principle in XRT is to give a therapeutic
dose to the tumor and minimize unwanted exposure
to surrounding normal tissues. Cardiac exposure is
nearly always the result of “stray” radiation as the
heart is almost never the actual target, except for rare
sarcomas or metastases. The primary ways in which
cardiac exposure has been reduced are better patient
selection, newer XRT technology, reducing field size,
and lowering the target dose (when appropriate). The
major cancers where cardiac exposure is a significant
clinical challenge are discussed in the following.
LYMPHOMA. High-dose ($40 Gy), extended field XRT
has played an important role in the curative treat-
ment of lymphoma since the 1960s. A common
approach for supradiaphragmatic disease was to
irradiate a mantle field (Figure 1) using an ante-
roposterior/posteroanterior technique with tissues
(including the heart) receiving a dose of w30 to 40 Gy
(15). Because patients were younger, they survived
for many decades after treatment, giving them
enough time to manifest RACD. Luckily, the treat-
ment approach has changed, and more recent pa-
tients are not exposed to this type of radiation(Figure 1). For patients who receive XRT and
chemotherapy, extended field is no longer
used, and XRT has evolved to small fields
(e.g., involved field, involved site, and
involved node [16]). However, these tech-
niques still require radiating sites of
pre-chemotherapy disease. Most recently, a
concept of irradiating only sites of residual
abnormalities after chemotherapy has
emerged (17). Through successive clinical
trials, the prescription XRT dose has been
lowered from >40 Gy to 20 to 30 Gy,
depending on risk factors (17). In addition,
advanced delivery techniques like deep
inspiratory breath hold (DIBH) (18) and pro-
ton therapy (19) have been used in select
cases to further reduce cardiac exposure.
DIBH pulls the heart inferiorly and allows
treatment of upper mediastinum with less
cardiac exposure. Because protons can stop at
a finite distance, normal tissue distal to the
target is avoided. All these modifications
have reduced exposure in many patients to
close to zero with almost no risk of RACD.
However, in some patients, even with all
modern treatment planning, especially those
with lower mediastinal disease, there can still
be significant cardiac exposure with mean
heart doses >10 Gy (20,21). When evaluating
these patients, discussion with the radiation
oncologist to understand RACD risk
is important.
BREAST CANCER. XRT (Figures 1 and 2) is used after
lumpectomy for most patients treated with breast
conservation therapy, because it improves survival
(22). Tangential fields used for breast conservation
historically extended from the midline to the mid-
axillary line. For left-sided lesions, the tangent
fields often included a small portion of the left heart
and left anterior descending artery, leading to cardiac
events (23). As a result, historical data showed that
patients who received radiation had higher rates of
RACD versus those who did not (24). A systemic re-
view of total heart doses delivered from 2014 to 2017
was down to 3.6 versus 5.4 Gy for 2003 to 2013 (25). At
an experienced center, it is exceedingly rare to have a
mean heart dose of >1 Gy when treating the left breast
without any nodal involvement. Only rare patients
with challenging anatomy (tumor beds in the medial
part of the breast and with the heart hugging the
chest wall) have mean heart doses of >1 Gy, despite
DIBH. For patients with higher risk and/or advanced
disease, in addition to the breast/chest wall, the
CENTRAL ILLUSTRATION Various Manifestations of Radiation-Associated Cardiac Disease
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908regional lymph nodes also often require adjunct ra-
diation (either after lumpectomy or mastectomy). The
lymph node region that is most challenging to treat is
the internal mammary lymph node (IMN) chain. A
variety of techniques have been used to treat IMN
(26), but because of their location, it is unavoidable
that the cardiac exposure increases (27). Despite evi-
dence that IMN radiotherapy (IMN-RT) was benefi-
cial, most radiation oncologists in the 2000s were not
delivering IMN-RT because of cardiotoxicity concerns
(28). However, recent data have shown that even
patients with relatively early-stage breast cancer
benefit from regional node irradiation and IMNirradiation is increasing (29,30). Multiple techniques
have been developed to limit cardiac exposure with
significant dose reduction over a few decades (27,31).
Current techniques are 3-dimensional conformal ra-
diation with heart blocking, DIBH, and prone posi-
tioning. Intensity-modulated radiation/arc therapy
uses more beams than 3-dimensional approach and
improves high-dose conformality while preserving
target coverage. Lastly, proton therapy can further
limit cardiac exposure in breast cancer patients (32).
Dosimetric studies have shown the proton therapy
can significantly reduce the heart exposure versus
photon therapy (33). The benefit of protons is most
TABLE 1 Prevalence of Various Manifestations of RACD in Observational Studies






Congestive heart failure  HL (91 cases and 278 controls
of 2,617 survivors between
1965 and 1995) (1)
 Mean LV dose 16.7 Gy
Mean LV dose, Gy Rate ratio of disease Mean LV dose, Gy 25-yr cumulative risk
1–15 1.27 1–15 4.4%
16–20 1.65 16–20 6.3%
21–25 3.84 >20 13.3%
>25 4.39
 BC (59 cases and 111 controls,
between 1998 and 2013) (2)
 Mean cardiac dose 2.5 Gy
Odds ratio
HF 9.1
HF preserved EF 16.9
HF reduced EF 3.17
Valvular  HL (89 cases and 200 con-
trols of 1,852 Hodgkins sur-
vivors between 1965 and
1995) (3)
Mean LV dose, Gy Relative risk of disease Mean LV dose, Gy 30-yr cumulative risk
<30 1.4 <30 3%
31-35 3.1 31-35 6.4%
36-40 5.4 36-40 9.3%
>40 11.8 >40 12.4%
Ischemic  HL (325 cases and 1,204
controls of 2,617 Hodgkins
survivors between 1965 and
1995) (4)
7.4%/Gy, no upper threshold, linear risk
 BC (963 cases and 1,205
controls of 2,168 breast can-
cer survivors between 1958
and 2001) (5)
 Mean cardiac dose 4.9 Gy
7.4%/Gy, no upper threshold
CV diseases (CHF, ischemic,
valvular, pericarditis)
 HL (2,524 patients between
1965 and 1995) (6)
Odds ratio For patients treated before 25 yrs of age,
cumulative incidences at $60 yrs were
20%, 31%, and 11% for ischemic, valvular,
and HF as first events, respectively.
Ischemic heart disease 2.7
Valvular heart disease 6.6
HF 2.7
 BC (34,825 women 1976–
2006) (7)
 Mean cardiac dose 6.3 Gy for
left-sided and 2.7 Gy for
right-sided tumors
Higher incidence ratios for left- vs. right-sided
tumors: acute myocardial infarction 1.22, angina
1.25, pericarditis 1.61, valvular heart disease 1.54
No difference in mortality
CV events  BC (meta-analysis of 289,109
patients from 13 observa-
tional studies) (8)
Left-sided breast cancer had a higher risk of CV
death than those who received XRT for a right-
sided breast cancer (RR: 1.12; p < 0.001)
Difference in CV mortality between left- vs.
right-sided breast XRT was more apparent
after 15 yrs of follow-up (RR: 1.23;
p < 0.001).
Electrical abnormalities  BC (44,423 patients between
1982 and 2005) (52)
The unadjusted IRR was 1.09 (95% CI: 0.91–1.30)
for CIED implants among women receiving XRT
compared with nonirradiated women and the IRR
was 1.13 (95% CI: 0.93–1.38) when adjustments
were made.
XRT for breast cancer does not increase the
long-term risk of severe ventricular
arrhythmias or cardiac conduction
abnormalities.
Autonomic dysfunction  HL (263 patients 19 yrs after
XRT) (10)
Elevated resting heart rate and abnormal heart rate
recovery increased in XRT patients: odds ratio:
3.96 and 5.32, respectively.
Abnormal heart rate recovery associated with
increased all-cause mortality (hazard ratio:
4.60)
Pericardial diseases  HL (377 patients) (11) Pericarditis observed with irradiation of the entire
pericardium was 20%. With left ventricle
shielding, this rate was decreased to 7%, and
with subcarinal block, it was further reduced to
2.5%
 Esophageal cancer (214 pa-
tients between 2001 and
2010) (12)
Patients who receive high doses of radiation are at
risk for pericardial effusions (incidence of 36%,
8% symptomatic)
Aortic calcification  Various cancers receiving
mediastinal XRT (13)
In the inoperable Placement of Aortic
TraNscathetER valve trial cohort, 15% had a
porcelain aorta, with a high proportion likely due
to prior mediastinal radiation.
Pulmonary function
abnormalities
 HL (145 patients between
1980 and 1990) (14)
>3 yrs after treatment, 32% of XRT patients and
37% of XRTþchemothreapy patients had FVC
values <80% of predicted, and 7% of patients
had a DLCO <80%. Mantle XRT was predictive
of FVC and DLCO reduction.
BC ¼ breast cancer; CI ¼ confidence interval; CIED ¼ cardiovascular implantable electronic device; CV ¼ cardiovascular; DLCO ¼ diffusion lung capacity; EF ¼ ejection fraction; FVC ¼ forced vital capacity;
HF ¼ heart failure; HL ¼ Hodgkins lymphoma; IRR ¼ incidence rate ratio; LV ¼ left ventricle; RACD ¼ radiation-associated cardiac disease; RR ¼ relative risk; XRT ¼ mediastinal radiotherapy.
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TABLE 2 Risk Factors and Long-Term Manifestations of Chest and
Mediastinal Radiotherapy
Risk factors for developing RACD and RAPD
 Younger age at the time of XRT (<50 yrs)
 Presence of cardiovascular risk factors or established cardiopulmonary
disease
 Lack of shielding or cobalt as a source of radiation
 High cumulative dose(>30 Gy) or high dose of radiation fractions
(>2 Gy/day)
 Tumor in or next to the heart
 Anterior or left chest radiation
 Concomitant chemotherapy (e.g., anthracyclines)
Potential manifestations of chest and mediastinal XRT
Pericardium
 Constrictive pericarditis due to extensive fibrous thickening, adhesions,
chronic constriction and can be associated with chronic pericardial effusion.
Associated with significantly higher surgical mortality
Cardiac muscle
 Diffuse subclinical myocardial fibrosis with associated progressive
systolic and diastolic dysfunction
 Nonischemic cardiomyopathy can occur as an advanced stage of the disease
due to extensive fibrosis with severe diastolic dysfunction and signs and
symptoms of heart failure (heart failure with preserved ejection fraction
more common than reduced ejection fraction)
 Ischemic cardiomyopathy can occur due to advanced CAD
Valves
 Valve apparatus and leaflet thickening, fibrosis, shortening, and
calcification predominant on left-sided valves
 Thickening and calcification of aortomitral curtain very commonly seen
 Valve regurgitation more common than stenosis
 Aortic valve stenosis most common stenotic lesion
Coronary artery disease
 Accelerated CAD often seen at a much younger age
 Concomitant atherosclerotic risk factors further enhance development
of CAD
 Can occur #5 yrs after exposure
 Coronary ostia and proximal segments are typically involved
 CAD significantly increases the risk of myocardial infarction and death
Carotid artery disease
 Radiotherapy induced lesions are more extensive, involving longer
segments and atypical areas of carotid segments
Other vascular disease
 Calcification of the ascending aorta and aortic arch (porcelain aorta)
 Lesions of any other vascular segments present within the radiation field
Conduction system disease
 Ectopy, tachyarrhythmia, baseline sinus tachycardia and autonomic
dysfunction commonly seen
 Increased risk of pacemaker implantation due to conduction system disease
Lungs
 Progressive pulmonary fibrosis
 Recurrent pleural effusions
CAD ¼ coronary artery disease; RACD ¼ radiation-associated cardiac disease; RAPD ¼ radiation-
associated pulmonary disease; XRT ¼ radiotherapy.
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910meaningful when IMN chain is included in the target
volume (34). Encouraging early outcomes with pro-
ton therapy have demonstrated similar acute
toxicity, local control, and very low mean heart
doses (35,36). For left-sided cases with IMN-RT, the
mean heart dose with proton therapy is typically
around 1 Gy versus 4-5 Gy with photon therapy.
Based on this, a phase 3 national randomized trial
(RADCOMP [Radiotherapy Comparative Effective-
ness]/RTOG [Radiation Therapy Oncology Group]
3510) to determine whether proton therapy canreduce the rate of 10-year major cardiac events by
40% is ongoing.
LUNG CANCER. As the population of patients
receiving XRT for lung cancer is older with multiple
cardiovascular risk factors, the emphasis is to inten-
sify therapy to improve survival. However, a
meta-analysis has demonstrated worse survival in
patients receiving XRT versus surgery alone (37). For
many years, 3-dimensional conformal radiation was
the standard approach for lung XRT, with significant
portions of the heart receiving 60 Gy (mean 30 to 40
Gy). Renewed interest in RACD has developed after
reports of worse overall survival (28.7 months) in the
high-dose versus standard arm (21.7 months) (38),
with volume of the heart receiving >35 Gy indepen-
dently predicting poor survival. Phase 2 trials have
shown improved survival using proton therapy and
chemotherapy compared with photon therapy (39).
Based on this, a phase 3 randomized trial (Comparing
Photon Therapy To Proton Therapy To Treat Patients
With Lung Cancer [RTOG 13-08]; NCT01993810)
comparing proton versus photon therapy in patients
receiving definitive chemoradiation for stage 2 to 3
non-small cell lung cancer is ongoing. Also, target
volumes vary greatly based on tumor location. In a
patient with an upper lobe primary tumor and upper
paratracheal lymph nodes, cardiac exposure is close
to zero versus a patient with a left lower lobe tumor
and subcarinal lymph node involvement (>50 Gy).
Thus, when estimating a patient’s cardiac risk, it is
essential to review the actual treatment plan.
FUTURE OUTLOOK. Patients treated in 2019 will un-
doubtedly have lower rates of RACD than previously
treated patients due to efforts in reducing cardiac
exposure. Although significant progress has been
made in minimizing unwanted cardiac exposure, the
following questions remain unanswered (40). Is there
a cardiac dose that is sufficiently safe? Are there
certain cardiac parts can tolerate XRT versus others?
Is it more dangerous to deliver a high XRT dose to a
small cardiac area versus low dose to a large area?
Do new chemotherapy agents also have potential
additive detrimental effects? In many cases, we are
forced to decide between optimizing target coverage
and cardiac exposure. The treatment planning re-
quires the radiation oncologist to pick among a vari-
ety of radiation techniques. In doing so, they must
pick the optimal particle, angles, energy, delivery
system, target coverage, and because there are so
many unanswered questions about the relationship
between dose, volume and cardiac substructures,
there is significant practice variation when it comes to
XRT delivery.
FIGURE 1 Evolution of XRT Techniques
In a patient with lymphoma, significantly higher cardiac exposure occurred with mantle radiation (A and C) versus involved node XRT (B suggests large and D suggests
smaller nodal involvement). In a patient with left breast cancer, comparison plans suggest a significantly higher amount of cardiac involvement with partially wide
tangent field (E) and (F) photons/electrons versus proton therapy (G). Adapted with permission from Maraldo et al. (20) and MacDonald et al. (32). XRT ¼ radiotherapy.
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Our current knowledge about deleterious ef-
fects of XRT is mainly derived from older
animal experiments, which do not necessarily
reflect contemporary XRT. Also, the factors asso-
ciated with progression from acute injury to chronic
RACD are still not fully understood. Early events in
the post-radiation cascade are loss of endothelial
cells with subsequent inflammatory responses,
driving vascular damage. For chronic RACD, fibrosis
appears to be the key process through which damage
ensues (Figure 3). A central event promoting patho-
logical fibrosis is the long-term differentiation of fi-
broblasts into activated myofibroblasts, a process
strongly driven by transforming growth factor-beta
(41). Activated myofibroblasts, in turn, produce
collagenous extracellular matrix components,
increasing tissue stiffness, and thus impairing
structure elasticity and function. Ionizing radiation
can also influence deoxyribonucleic acid methyl-
ation profiles of cells, thus modifying gene expres-
sion, and of noncoding ribonucleic acids, some of
which can modulate key factors in the development
of fibrosis.MANIFESTATIONS
RACD is a spectrum of deleterious effects, ranging
from preclinical findings to symptomatic disease
(Table 1, Central Illustration). Late effects manifest
decades after treatment, resulting in a variety of
complications including: myocardial fibrosis/
dysfunction, congestive heart failure, valvular heart
disease, vasculopathy including CAD, pericardial
disease, and conduction abnormalities. Clinically,
there is substantial overlap resulting in management
challenges, as many patients have additional radia-
tion damage to lung parenchyma, and present with
nonspecific dyspnea or fatigue, which can be difficult
to differentiate from cardiac disease and may further
impact cardiac surgical risk.
MYOCARDIAL DISEASE AND HEART FAILURE. As a
result of prior XRT, there is evidence of myocardial
dysfunction (likely related to diffuse fibrosis) with
resultant impairment in functional capacity without
heart failure (shown in breast cancer survivors) and
heart failure with preserved ejection fraction (in both
lymphoma and breast cancer survivors) appears more
prevalent than systolic dysfunction (1,2,42). The
FIGURE 2 Evolution of XRT Dosage
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Reduction in mean heart radiation doses for left breast cancer by (A) year and (B) different techniques. Adapted with permission from Drost et al. (25).
XRT ¼ radiotherapy.
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912anterior position of the right ventricle makes it
susceptible to damage, although this is often under-
recognized due to suboptimal visualization.
Biventricular radiation fibrosis tends to follow a non-
ischemic pattern. However, coexistent radiation
induced micro- and macrovascular disease can result
in ischemia/infarction and regional fibrosis. The
detrimental effects of radiation tomyocardial function
can be compounded by chemotherapy, particularly
anthracyclines (43), and HER-2/neu receptor antago-
nist trastuzumab. Recent data suggest that trastuzu-
mab may have a radio-sensitizing effect on breast
cancer cells, although it remains unclear whether
similar effects occur on normal healthy cells (44).
VALVULAR HEART DISEASE. This usually manifests
as progressive valve thickening and calcification,
resulting in valve restriction presenting as stenosis or
regurgitation. Patients usually become symptomatic
later than coronary disease, and awareness of this
latency is important, given that asymptomatic survi-
vors treated over 20 years ago have increased risk of
aortic regurgitation (60% vs. 4%), tricuspid regurgi-
tation (4% vs. 0%), and aortic stenosis (AS) (16% vs.
0%) compared with patients treated within 10 years
(45). Radiation-associated valvular thickening and
calcification are more extensive, often involving
surrounding structures such as the annulus, sub-
valvular apparatus, and aortomitral curtain, often
resulting in a mixed picture of stenosis/regurgitation
in multiple valves. Left-sided valves are more ofteninvolved versus right-sided. Aortomitral curtain
thickening/calcification is a hallmark of previous
heart irradiation and its extent is associated with
mortality (46).
PERICARDIAL DISEASE. Although acute pericarditis
following XRT tends to be self-limiting, some patients
progress to chronic pericardial involvement. In
Hodgkin’s patients, 20% had pericarditis observed
with irradiation of the entire pericardium (11). Chronic
pericardial inflammation results in a thickened, rigid,
and often calcified pericardial sac. Loss of distensi-
bility can result in ventricular interdependence and
constrictive physiology. Given that most RACD pa-
tients have some restrictive physiology, it can be
difficult to distinguish between restriction (due to
underlying myocardial fibrosis) and constriction.
VASCULOPATHY. XRT-associated vasculopathy
manifests as both micro- and macrovascular disease
and is typically progressive, manifesting years after
initial exposure.
Radiation-associated coronary vasculopathy, typi-
cally affects the ostia or proximal coronary arteries;
however, the proximal right coronary artery, mid-left
anterior descending coronary artery, and mid-
diagonal branches are particularly involved among
patients with breast cancer and left-sided XRT (23).
The predilection for the ostial left main and right
coronary artery likely relates to coronary artery po-
sition within the anterior radiation field and perhaps
a greater propensity for intimal proliferation. The
FIGURE 3 Pathophysiology of RACD








































Overt symptoms due to cardiopulmonary disease
Progressive
myocardial fibrosis
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Effect of XRT on various organs. LV ¼ left ventricular; RACD ¼ radiation-associated cardiac disease; XRT ¼ radiotherapy.
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913lesions tend to be longer, tubular, and concentric and
are often noncalcific. Myocardial ischemia can com-
pound concurrent myocardial dysfunction. The risk
of myocardial infarction proportionally increases
with duration from radiation exposure and is highest
in those who received treatment when aged <20 years
(47). Microvascular disease is less well studied,
although it appears to contribute to myocardial
dysfunction via ischemia and resultant fibrosis. Large
vessel vasculopathy often involves the thoracic aorta
and arch branch vessels, manifesting as atheroscle-
rotic disease, although regional thrombosis leading to
vessel occlusion or embolic stroke can also occur. This
can assume added significance because it may pre-
clude percutaneous intervention or surgical access
(porcelain aorta) (48).CONDUCTION SYSTEM DYSFUNCTION. XRT results
in fibrosis of conduction pathways and subsequent
abnormalities, including atrioventricular block, sick
sinus syndrome, atrial fibrillation, and ventricular
tachyarrhythmias, that can occur years later (49,50).
Infranodal and right bundle branch blocks are com-
mon, with the anteriorly located right bundle being
particularly susceptible. There is a higher proportion
of RACD patients who require pacemaker post-
operatively (51). However, in a recent study of
breast cancer survivors, there was no increased risk of
ventricular tachyarrhythmias or conduction abnor-
malities due to XRT (52). Autonomic dysfunction has
been poorly studied, although inappropriate sinus
tachycardia has been recognized as a sign of exten-
sive RACD and can result in reduced exercise capacity
FIGURE 4 Imaging in RACD
Prior chest XRT




















Re-assess every 5 years







• CT chest to evaluate lungs, heart and aorta
• PFTs with DLCO
• CMR (if constriction/restriction suspected)
• Left/right heart catheterization
• Carotid ultrasound
Search for symptoms and signs suggestive of RACD:
• Pericardial disease
• Valvular heart disease
• LV/RV dysfunction
• Coronary artery disease
• Extracardiac vascular disease
• Conduction system disease
Screening echocardiography
(5 years after exposure in high risk patients)
(10 years after exposure in the others)
Functional non-invasive stress test for
CAD detection
(5 to 10 years after exposure in high risk patients)
? Baseline pre-XRT echocardiography
Suggested screening and diagnostic algorithm for RACD. CAD ¼ coronary artery disease; CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography;
DLCO ¼ diffusion lung capacity; PFT ¼ pulmonary function test; RV ¼ right ventricular; other abbreviations as in Figure 3.
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mediated cardiomyopathy (10,53).
PULMONARY DISEASE. RAPD occurs as a longer-term
consequence of the repair process resulting in pul-
monary fibrosis, leading to symptoms due to reduc-
tion in forced vital and diffusing capacity, RAPD
should be particularly considered when determining
suitability for cardiac surgery, because pulmonary
complications are a major source of perioperative
morbidity and mortality (54). This is especially
problematic after repeat cardiac surgery, where
recurrent pleural effusions, severely reduced lung




Patients should be educated about the risk of long-
term RACD before treatment, and consideration
could be given to a cardiology consultation, especiallyin those with additional risk factors (Table 2). Given
the long latency and poor outcomes of RACD, serial
screening of cancer survivors is recommended (56)
(Figure 4). Transition from pediatric to adult ser-
vices is also important to ensure adequate follow-up.
Typically, screening for CAD should commence <5
years and valvular heart disease w10 years after XRT,
with subsequent imaging then performed at 5-year
intervals (56). For patients with conventional risk
factors, screening echocardiography is recommended
in the fifth year after treatment, and noninvasive
stress testing is recommended #5 years after treat-
ment and at 5-year intervals, with a preference for
stress (dobutamine or exercise) echocardiography
(57). Traditional risk factors should be aggressively
managed as they act synergistically with radiation
exposure, to increase the risk for major coronary
events from 2 to 7% (5). Biomarkers such as brain
natriuretic peptide and troponin can also be poten-
tially used to identify asymptomatic patients at risk
of future events (58). The role of various imaging











Effusion þ þþþþ   þ þ   
Pericarditis þþ þþ   þ þþþ   
Constriction þ þþþþ þ  þþ þþþþ  þþ 
Cardiac muscle disease
Subclinical myocardial fibrosis ? ?    þþþ  ? 
Nonischemic þþ þþ þ þ þþ þþþþ þþþþ þþ 
Ischemic þþþþ þþþþ þþþþ þþþ þþþ þþþþ þþþþ þþ 
Heart failure with preserved ejection fraction þþ þþþþ þþþ ? þþ þþ þþþþ þþ 
Valvular disease ? þþþþ þþþþ ? þþþ þþþ þ þþ 
Conduction system disease þþþþ þþþ þþ ? þþ þþ   
Coronary artery disease þþþ þþþ þþþ þþþþ þþþ þþ þþþþ þþ 
Extracardiac vascular disease     þþþþ    þþþþ
CMR ¼ cardiac magnetic resonance; ECG ¼ electrocardiogram; LHC ¼ left heart catheterization; MDCT ¼ multidetector computed tomography; RACD ¼ radiation-associated
cardiac disease; RHC ¼ right heart catheterization.
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915modalities in RACD is discussed in the following text
(Table 3).
ECHOCARDIOGRAPHY. Echocardiography is the first
imaging technique to screen, diagnose, and monitor
RACD (56). Detection of any structural abnormal-
ity, measurement of ventricular performance, and
evaluation of valvular heart disease severity (calcifi-
cation, fibrosis/rigidity, retraction, stenosis, regurgi-
tation) are the key echocardiographic findings in
RACD. For both constrictive (e.g., prominent respir-
ophasic diastolic bounce of the septum, significant
inspiratory variation of mitral E-wave velocity, he-
patic vein expiratory diastolic flow reversal, annulus
reversus) and effusive pericardial pathophysiology
(i.e., features of cardiac tamponade), echocardiogra-
phy is the modality of choice, whereas it is less useful
for diagnosing pericardial thickening and calcifica-
tions (56). Although left ventricular (LV) ejection
fraction (LVEF) is the most common tool in global
systolic function assessment, subtle changes may be
missed due to dynamic changes in loading conditions
or measurement variability (59). RACD-related car-
diac dysfunction is defined as a >10% decrease in
LVEF to a value <50% to 53%, confirmed by repeated
imaging 2 to 3 weeks after the baseline diagnostic
study (60). Three-dimensional echocardiography–
measured LVEF appears more useful and is more
reproducible for serial assessment (61). Contrast
echocardiography, though it improves delineation of
the LV endocardial borders, remains less accurate
than 3-dimensional echocardiography (61). Also,
because the majority of patients have preserved
LVEF, diagnosis is challenging (2). Reductions in
systolic myocardial deformation are detectedimmediately and 2 months after XRT, in the absence
of detectable reductions in LVEF. Strain echocardi-
ography demonstrated abnormal global longitudinal
strain (GLS) and global circumferential strain in 33%
and 21.7%, respectively, whereas depressed LVEF was
detected in only 5.7% of patients (62). Abnormal GLS
was also correlated with reduced quality of life and
lower mean 6-min walk distances. The lower observer
variability of GLS allows for easier recognition of the
change in systolic function when compared with
LVEF (63). Thus, whereas reduced EF is a late finding
in RACD, abnormal strain may herald early-onset
disease and is increasingly being incorporated into
screening. In RACD patients with preserved LVEF
undergoing cardiac surgery, LV-GLS <14.5% was
associated with higher mortality, versus with normal
LV-GLS (64). However, thresholds for GLS abnormal-
ity in such patients remain unknown.
Echocardiography is highly sensitive in detecting
valvular disease (56,65). The earliest change relates to
progressive valvular retractions accompanied by
regurgitation occurring within the first 10 years. The
progression to fibrotic thickening and calcification
occurs much later, with stenosis often appearing 20
years after XRT (56,65). Mitral and aortic valve re-
gurgitations are the most common defects, and when
stenosis occurs, it most commonly affects the aortic
valve. Progressive thickening and calcification of the
aortomitral curtain is a characteristic finding (46).
Though transthoracic echocardiography is often suf-
ficient for diagnosis, transesophageal echocardiogra-
phy is occasionally performed for further diagnostic
refinement. However, given the possibility of
XRT-associated esophageal injury, care should be
taken to minimize procedural time.
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limited to the assessment of the presence and extent
of regional wall motion abnormalities. Stress-induced
wall motion abnormality is a reliable indicator of
myocardial ischemia, which is highly sensitive and
specific (>80%) for angiographically assessed epicar-
dial CAD (22,30).
MULTIDETECTOR CARDIAC COMPUTERIZED
TOMOGRAPHY. Multidetector computed tomography
(MDCT) is commonly employed for evaluation of
aortic, valvular, myocardial, and pericardial calcifi-
cation on either contrast or noncontrast imaging. Pre-
operative assessment for aortic calcification is
important to determine suitability for aortic cross-
clamping and cannulation in patients undergoing
cardiac surgery. Significant valvular and/or annular
calcification may preclude valvular repair. For trans-
catheter valve therapies, 4-dimensional MDCT is
crucial for pre-procedural planning, including
assessment of annular shape and size (aortic, mitral,
and tricuspid) and ileofemoral vasculature (66).
MDCT is also useful to evaluate extracardiac struc-
tures for surgical planning in redo surgeries (67).
Extensive mediastinal fibrosis or lack of a safety
margin between the sternum and adjacent structures
may necessitate a nonsternotomy/transcatheter
strategy. Pulmonary fibrosis has an adverse impact on
survival in RACD and should be evaluated (54). Peri-
cardial calcification, thickening, venacaval enlarge-
ment, and ventricular conical deformity are
suggestive of pericardial constriction (68). Also, cor-
onary calcium scoring and computed tomography
(CT) angiography can be useful in RACD for its nega-
tive predictive value, with no atherosclerosis sug-
gesting a very low risk. However, many patients have
severe noncalcific stenoses rendering calcium scoring
less useful, and in cases with extensive coronary
calcification, assessment for luminal stenosis on CT
angiography becomes difficult due to
blooming artifact.
NUCLEAR SCINTIGRAPHY. Single-photon emission
CT and positron emission tomography can assess
myocardial ischemia in RACD. Studies are limited by
small numbers, but show that 12% of asymptomatic
patients have stress induced perfusion defects; and in
patients receiving both XRT and chemotherapy, a
high proportion of new perfusion defects (69,70).
CARDIAC MAGNETIC RESONANCE. Cardiac magnetic
resonance (CMR) can provide useful simultaneous
functional and structural data, enabling detection of
coronary, valvular, and pericardial disease. Cine im-
aging allows assessment of ventricular mass, vol-
umes, function, and regional wall motionabnormalities, which can then be correlated with late
gadolinium enhancement to establish regions of
viability, scar, and nonischemic fibrosis. Valvular
function can be assessed by calculation of trans-
valvular gradients and regurgitant volumes.
Radiation-induced pericardial thickening, effusions,
and features of constrictive physiology are suggested
by ventricular conical deformity, diastolic septal
bounce, diastolic chamber restraint, inferior ven-
acaval enlargement, and respirophasic septal shift,
whereas increased pericardial signal intensity on
edema weighted T2 imaging and late gadolinium
enhancement suggests pericardial inflammation (71).
First-pass perfusion imaging (using pharmacological
stressors) can identify underlying myocardial
ischemia. T1 mapping may prove useful for RACD, but
requires further investigation. CMR is not routinely
recommended, but can be useful for assessment of
ischemic/nonischemic myocardial fibrosis, assess-
ment of pericardial constriction, and as an adjunct to
echocardiography in technically difficult subjects.
LEFT AND RIGHT HEART CATHETERIZATION. Inva-
sive catheterization provides complementary and
confirmatory information to noninvasive imaging.
Left heart catheterization allows assessment of coro-
nary stenosis severity. Right heart catheterization is
useful for calculation of intracardiac and pulmonary
pressures. Simultaneous left and right heart mea-
surements allow for evaluation of constrictive phys-
iology and cardiac index, with a low index prompting
evaluation for restrictive cardiomyopathy. Because
proximal CAD may be underappreciated, especially if
ostial in location, there should be a low threshold for
utilizing intravascular ultrasound, particularly in the
setting of pressure damping or contrast reflux.
EXTRACARDIAC VASCULAR ULTRASOUND. Many
instances of extensive radiotherapy involve the ca-
rotid and subclavian arteries. As a result, the clinical
threshold to perform ultrasound of these vessels
should be low. Additionally, pre-operative internal
mammary artery (72) and vein mapping allows for
assessment of the quality and availability of coronary
bypass conduits.
RADIATION-ASSOCIATED PULMONARY DISEASE.
Subjects with a history of thoracic radiation should be
screened for RAPD, as it is associated with reduced
survival in RACD (54). Typically, this manifests as
pulmonary fibrosis with traction bronchiectasis in
severe cases. Clinical examination, chest x-ray, pul-
monary function testing (lung volumes and diffusion
lung capacity), and dedicated high-resolution CT
chest is generally recommended.


































All evaluation and management should be performed at an experienced center with a heart team of cardiologists and cardiac surgeons experienced in management of RACD. Many treatment decisions might























Significant CADSignificant CADSignificant CADSignificant CADSignificant CAD Significant CAD
NoYes NoYes NoYes
No Yes No Yes
Syntax ≥22Syntax <22Syntax ≥22Syntax <22
At least moderate MS/MR
High-risk pulmonary findings
And porcelain aorta
At least moderate MS/MRAt least moderate MS/MR
Normal pulmonary findings
but with porcelain aorta
Normal pulmonary findings
And no porcelain aorta
Lung or aortic findings
No prior cardiac surgery, Severe AS/AR
Suggested management algorithm of patient with RACD. AR ¼ aortic regurgitation; AS ¼ aortic stenosis; AVR ¼ aortic valve replacement; CABG ¼ coronary artery
bypass grafting; MR ¼ mitral regurgitation; MS ¼ mitral stenosis; MVR ¼ mitral valve replacement; PCI ¼ percutaneous coronary intervention; TAVR ¼ transcatheter
aortic valve replacement; TMVR ¼ transcatheter mitral valve replacement; other abbreviations as in Figures 3 and 4.
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All patients with a prior cancer history should be
questioned about radiation or cardiotoxic chemo-
therapy. Often, radiation exposure is only realized
when cardiac testing suggests a more extensive
calcific or fibrotic process than typical for age. An
experienced team of cardiologists, imaging special-
ists, interventionalists, and cardiothoracic surgeons
is recommended to guide therapeutic strategies (73).
Physicians treating complex patients with RACD
have an important task of resetting patient expecta-
tions and educating regarding the poorer outcomes in
RACD. A suggested approach to patients with com-
plex symptomatic RACD, based on our experience, is
discussed in the following text and shown in Figure 5.
MEDICAL THERAPY
Medical therapy is typically undertaken according
to standard guidelines. Pericardial constriction
may warrant a trial of anti-inflammatory therapy,
in case of reversibility (74). The benefit of heart
failure pharmacotherapy in subclinical myocardialdysfunction remains unknown. Although no drug is
currently approved for treatment of RACD, some
studies highlight the potential therapies studied in
animal models (75). Statins might have benefits on
radiation-induced fibrosis (76). Prior reports have
showed that treating experimental animals with
angiotensin-converting enzyme inhibitors or angio-
tensin receptor blocker reduces radiation-induced
injury of normal tissue (77). Intraperitoneal mela-
tonin injection before XRT decreased vascular dam-
age, cardiac fibrosis, and myocyte necrosis observed
after 6 months (78). Recombinant human neuregulin-
1b prevented mitochondrial dysfunction early after
cardiac irradiation. At a later stage, it also decreased
fibrosis and cardiomyocyte hypertrophy (79). How-
ever, well-conducted prospective studies are lacking.
As a result of no definitive medical therapies for
RACD, most symptomatic patients require invasive
therapies to relieve significant lesions.
CARDIAC SURGERY
The surgical approach to RACD must take into ac-
count all the possible manifestations of RACD
FIGURE 6 A Patient With RACD Who Underwent Cardiac Surgery
Echo revealing significant mixed (stenotic and regurgitant) aortic and mitral valve disease and calcification of aortomitral curtain (A to C) Computed tomography
revealing no porcelain aorta or pulmonary (D and E) no obstructive coronary artery disease (F and G) schematic representation of Commando operation (aortic and
mitral valve replacement with reconstruction of aortomitral curtain) (H to K). RACD ¼ radiation-associated cardiac disease.
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indication for surgery is CAD or valvular heart dis-
ease, it should be assumed that there would be radi-
ation injury to the aorta, ventricles, pericardium,
lungs, and chest wall. As a result, pre-operative
evaluation should include echocardiography, coro-
nary angiography, MDCT, and pulmonary function
testing. Strong consideration should be given to CMR
and combined left and right heart catheterization
with simultaneous pressure measurements if there is
concern for constrictive pericarditis versus
restriction.
Many RACD patients have some degree of restric-
tive lung disease with decreased lung volumes.
Although there are no strict cutoffs, forced expiratory
volume at 1 min <1 l and diffusion lung
capacity <40% should raise concerns that post-
operative ventilator weaning may be difficult. It isalso important to recognize that these patients often
have undrained pleural effusions that contribute to
poor pre-operative study metrics, some or all of
which may improve with correction of the valve and
coronary lesions. The combination of very poor pul-
monary function numbers and pulmonary fibrosis on
MDCT should raise concerns of significant RAPD.
Once the decision has been made a patient is
potentially a surgical candidate, MDCT is crucial for
surgical planning (67). Even in primary surgery,
radiation-induced scarring (54) can result in the
innominate vein and other vascular structures being
in close sternal proximity, making sternotomy haz-
ardous. A careful 3-dimensional MDCT will allow for a
full understanding of aortic, valvular, and intra-
valvular calcium, and in particular the location and
extent of mitral annular calcification. Severe
circumferential mitral annular calcification merits
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919pre-planning for an aggressive resection with anterior
annular debridement and reconstruction of the
intervalvular fibrosa, the “Commando” operation.
TIMING OF SURGERY. Many RACD patients have
complex disease involving multiple valves, coro-
naries, conduction system, and a degree of ventricu-
lar systolic and diastolic dysfunction. In our
experience, due to radiation injury to lungs and
pleura with resultant lymphatic dysfunction, RACD
patients are prone to complications relating to intra-
thoracic fluid retention after surgery, with a major
impact on recovery and quality of life after surgery. In
light of this, the normal criteria for surgical timing,
especially in valve disease, should be adjusted for
patients with RACD. Surgery should, in general, be
considered later in the course of disease than normal.
This is especially important in patients with multi-
valve disease where one valve may have severe
dysfunction and another mild or moderate. Redo
surgery in RACD carries a significant elevation in
operative risk and morbidity compared with non-
RACD surgery, such that every attempt should be
made to address all of the issues at the first operation
(55). Managing patient expectations is critical, as re-
covery after surgery cannot be expected to confer
near normal quality of life in all cases.
PRE-OPERATIVE PLANNING AND INTRAOPERATIVE
STRATEGIES. Pre-surgical evaluation should be sys-
tematic. Planning for cannulation, aortic cross
clamping, and managing valvular calcium and calci-
fication of the cardiac fibrous skeleton are important
(80). Calcification, which appears thin and patchy on
MDCT, will allow for safe aortic clamping. More dense
and circumferential calcification should merit plan-
ning for circulatory arrest and replacement of
the ascending aorta. With all but the most
straightforward-appearing aortic calcification on CT,
the surgeon should be comfortable planning to
remove or work around all the areas of calcification.
Therefore, a flexible perfusion and myocardial pro-
tection strategy would include: routine cannulation
of the right axillary artery with a side graft, routine
bicaval cannulation, and routine direct cannulation of
the ostium of the coronary sinus for retrograde car-
dioplegia. This approach allows for flexibility in
dealing with unexpected reconstruction problems in
what are often long, multicomponent operations.
SURGICAL PROCEDURES FOR RACD
CORONARY ARTERY BYPASS GRAFTING. Conduit
and available targets define options for coronary
bypass as in non-RACD patients. Internal thoracicarteries can potentially lie within the radiation field
in many patients; however, these arteries can be used
successfully after ascertaining their patency. Those
that appear small and fibrotic are best avoided;
however, the majority should be amenable. Vein
mapping before surgery is useful to define the quality
of venous conduits because last minute decisions are
best avoided. Radial artery conduits can be used with
similar criteria to non-RACD bypass surgery. Coro-
nary targets are likely to be diffusely calcified,
although less so than in patients with severe diabetes
or renal insufficiency. Diffuse disease may limit the
effectiveness of bypass despite a severe proximal
lesion; however, finding an adequate touchdown site
for a graft is usually not a problem.
AORTIC AND MITRAL VALVE REPLACEMENT.
Serious consideration should be given to replacing
both aortic and mitral valves even if 1 is moderately
diseased, because intra-operative options may be
limited by areas of calcium that can often span be-
tween the 2 valves. A common scenario exists in
which the aortic valve disease is severe and mitral
valve disease is moderate, often with posterior mitral
annular calcification. In this scenario, it is tempting
to replace the aortic valve and leave mild-to-
moderate mitral regurgitation. Although this result
may be initially acceptable, valvular disease in
radiation patients may progress rapidly, leaving a
patient with a functioning aortic prosthesis and pro-
gressively severe mitral valve disease within a few
years of surgery. In light of higher risk of reoperative
surgery in RACD, every consideration should be
made to perform a complete operation at the first
surgery (55).
Valve tissue in RACD is not normal, and tends to
thicken and scar progressively over time. There is a
very real risk in RACD of transforming a regurgitant
valve into a stenotic valve with repair, a situation that
will likely worsen with progressive fibrosis and
calcification. Replacement over repair is favored for
these reasons in patients with RACD affecting the
mitral valve, if intervention is required (51).
EXTENSIVE RECONSTRUCTION OF THE AORTOMITRAL
CURTAIN. Two major findings in RACD patients
complicate aortic and mitral valve surgery. The first is
confluent calcification extending from the aortic
annulus across the aortomitral curtain and involving
the anterior leaflet of the mitral valve (46). This can
complicate exposure to, and suture placement in, the
anterior mitral annulus or make safe replacement
impossible. If calcium is effectively debrided, there
may be little healthy tissue remaining to allow
adequate fixation and sealing of the valve. The
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920second finding is the small annular size of the aortic
and mitral annuli. This may relate to early radiation
exposure when the heart is still growing, to progres-
sive fibrosis and scar shrinkage, or a combination.
Small aortic root and small mitral annulus are a
common finding in this patient population. The
combination of severe fibrous skeleton calcification
and small annuli make a more aggressive approach to
double-valve replacement attractive. Division of the
aortomitral curtain and anterior mitral leaflet allows
for better exposure of the posterior mitral annulus for
debridement of calcification, suture placement, and
reconstruction. In the Commando operation, a patch
of autologous or bovine pericardium is fashioned to
repair and expand the dome of the left atrium,
the mitral annulus, aortomitral curtain, aortic
annulus, and aortic valve. This approach allows
for repair of the defect left by aggressive debridement
of calcium, adequate sealing of the 2 prosthetic
valves, and in most cases at least 1 valve size
increase in both aortic and mitral valves for more
physiological hemodynamics. This is especially
important if bioprosthetic valves are used with
consideration for future valve-in-valve trans-
catheter interventions.
CHOICE OF PROSTHESIS. Given the increased risk of
cardiac reoperation, mechanical prostheses are
appealing especially for younger patients undergoing
valve replacement in RACD (55). However, consider-
ation should be given to the fact that RACD patients
often have other medical comorbidities that may
affect their ability to take lifelong anticoagulation. In
such patients, placement of bioprostheses and sub-
sequent valve-in-valve transcatheter therapy as a
second operation appear attractive. Despite the ad-
vances in transcatheter mitral therapy, current tech-
nology is limited in the face of prior mitral repair and
mitral annular calcification (81). As valve-in-valve
transcatheter therapy evolves, double-valve replace-
ment with stented bioprostheses, combined with
aortomitral curtain patch and dual annular enlarge-
ment, should be considered as a first operation in
patients with contraindications to warfarin and
no comorbidities.
CARDIAC TRANSPLANTATION. A small series has
reported acceptable outcomes following cardiac
transplantation in RACD patients, but longer-term
survival is reduced relative to cardiac trans-
plantation in the nonradiation cohort, in part due to
higher risk of recurrent malignancy due to associated
immunosuppression (82). Hence, transplant candi-
dacy must be carefully decided on a case-by-case
basis in recognition of this increased risk.POST-OPERATIVE CONSIDERATIONS. Chronic pleural
and pericardial effusions are common with RACD
patients after surgery. Although in most cases these
are adequately treated with prolonged drainage,
pleural effusions recurring up to a few weeks after
surgery may require longer-term soft drainage cath-
eters. Conduction system disturbances are common,
especially with more aggressive reconstruction. Many
patients need more than a few days of temporary
pacing after surgery. Placement of permanent LV
epicardial pacing leads should be considered. Lead-
less pacemaker might be considered in patients with
limited venous access. Management of post-operative
diuresis is often difficult due to restrictive ventricles.
It should be anticipated that the normal course of
post-operative diuresis would be prolonged, often for
weeks. Another danger in applying “routine” cardiac
surgery management to these patients is over-
application of beta-blocker therapy. RACD patients
are often rate dependent for cardiac output, because
the ventricle is limited by fibrosis and varying stroke
volume. Higher pacemaker heart rates should be
considered for those patients who are dependent, and
nodal blocking agents should be limited.
SURGICAL OUTCOMES
Multiple studies have suggested that although oper-
ative mortality for RACD patients in experienced
centers may approach that for matched non-RACD
patients, long-term outcomes are demonstrably
worse, with XRT exposure emerging as an indepen-
dent risk factor (55,82,83) (Figure 7). In a study of 478
patients (173 RACD and 305 matched group without
RACD) undergoing cardiac surgery, a significantly
higher proportion of patients died in the RACD group
versus the comparison group (55% vs. 28%; p < 0.001)
over 7.6  3 years, despite similar EuroSCOREs (55).
Cardiac reoperation in RACD was associated with
significantly higher longer-term mortality. Similarly,
in patients with severe AS undergoing surgical aortic
valve replacement (AVR), patients with prior medi-
astinal XRT (n ¼ 173) had significantly worse longer-
term survival versus a matched cohort (n ¼ 173)
(84). Recently, it has been also shown that in patients
with moderate AS, those with prior XRT have a
similar rate of progression of AS versus a comparison
group. Despite that, the XRT patients had signifi-
cantly higher longer-term mortality, with prior XRT a
major risk factor for longer-term mortality (85). We
simply do not understand enough about the variation
in myocardial fibrosis, pulmonary disease, and the
impact of radiation-induced vasculopathy on
outcome to make meaningful predictions about who
FIGURE 7 Outcomes of RACD
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Different groups undergoing (A) cardiac surgery, (B) SAVR, (C) PCI, and (D) TAVR. Adapted with permission from Wu et al. (55), Donnellan et al. (83,84), and Reed et al.
(91). SAVR ¼ surgical aortic valve replacement; other abbreviations as in Figures 3 and 5.
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921is truly high risk for operative intervention. This
complex disease process demands the close attention
of a multidisciplinary team and the careful applica-
tion of less-invasive technologies when appropriate
(Figure 8). For those patients in whom the disease has
progressed to the point surgery is appropriate,
consideration should be given to performing the most
complete operation considering safety, valve and
coronary disease, fibrous skeleton reconstruction,
and aortic reconstruction as necessary to safely arrest
the heart. Although long-term outcomes remain less
favorable, patients without significant pulmonary
(54) or myocardial fibrosis may achieve excellentlong-term success with surgery. Future efforts must
be directed to determine which patients may benefit
the most from surgery.
PERCUTANEOUS
CARDIOVASCULAR INTERVENTIONS
Owing to the complexity and multifaceted disease
manifestations of RACD as well as lack of evidence
from randomized studies, management strategies
taking into consideration percutaneous cardiovascu-
lar interventions are best developed within a heart
team representing broad expertise (66,86–88).
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INDICATION AND TREATMENT SELECTION. Among
patients with RACD manifesting as chronic CAD, the
indication should follow the established recommen-
dations (86). Although patients with isolated 1-vessel
or 2-vessel CAD preferentially undergo percutaneous
coronary intervention (PCI), the treatment selection
of patients with multivessel CAD is more nuanced and
modified CAD extent, SYNTAX score, diabetic status,
and the presence of left main disease (89). Moreover,
the decision between PCI and coronary artery bypass
grafting should give priority to the ability to achieve
complete revascularization (and treatment of
concomitant valvular lesions), taking into account
pulmonary status and porcelain aorta. Specifically,
multivessel CAD (without valvular disease) with
SYNTAX score <22 should be preferentially treated by
PCI. Similarly, left main disease at the ostium and
shaft, as well as left main disease with SYNTAX
score <32, should be considered for PCI as long as
technically feasible (86).
In patients with RACD presenting with non–ST-
segment elevation acute coronary syndrome, the
timing of the intervention should follow initial risk
stratification with an invasive strategy recommended
within 2 h among very high-risk patients, within 24 h
among high-risk patients, and within 72 h among
intermediate-risk patients (90). Patients with RACD
presenting with acute coronary syndromes are pref-
erentially managed by PCI of the culprit lesion. In
patients with RACD presenting with ST-segment
elevation myocardial infarction, primary PCI consti-
tutes the therapy of choice.
OUTCOMES. Data are conflicting regarding outcomes
of patients with RACD undergoing PCI. Reed and et al.
(91) (Figure 7) reported increased longer-term all-
cause and cardiovascular mortality compared with
matched controls in an observational cohort of 314
patients that underwent PCI between 2000 and 2012.
Multivariable analysis identified previous XRT, SYN-
TAX score >11, balloon angioplasty and bare-metal
stents (BMS) as independent predictors of mortality.
Conversely, Fender et al. (92) observed no difference
in longer-term all-cause and cardiovascular mortality
in 115 patients with previous XRT compared with 450
propensity score–matched control patients undergo-
ing PCI between 1994 and 2013. However, the volume
and dose of radiation therapy appeared to modify
outcomes, with increasing radiation exposure being
associated with poorer long-term outcomes (93). The
same group reported a similar risk of repeat revas-
cularization among patients with RACD indicating theabsence of a significantly increased risk of target
lesion revascularization or stent thrombosis (94).
TECHNICAL CONSIDERATIONS. Drug-eluting stents
should be the default device (86). Compared with
BMS, drug-eluting stents have been shown superior
in terms of efficacy (restenosis, target-lesion revas-
cularization, major cardiac events) and at least as safe
(95,96). More recent evidence in patients with mul-
tivessel and left main CAD indicates substantial im-
provements in terms of efficacy compared with
previous trials comparing coronary bypass and BMS
(97–99). In terms of vascular access, the radial
approach should be preferred, analogous to patients
without RACD (86). However, these findings need to
be qualified in terms of operator experience and
technical feasibility. Specifically in the setting of pa-
tients with RACD, ostial disease of the right coronary
artery or left main may be more challenging in terms
of guiding catheter selection and position. Intra-
coronary imaging may be considered to guide and
optimize treatment of patients with RACD undergo-
ing PCI (86). Selection of stent dimension (diameter
and length), as well as optimization of procedural
outcomes, may be guided by intracoronary imaging
with use of optical coherence tomography or intra-
vascular ultrasound.
LONG-TERM FOLLOW-UP CARE. Following PCI, the
duration of dual antiplatelet therapy in patients with
RACD should be governed by the underlying clinical
setting (chronic vs. acute coronary syndromes) and
bleeding risk (100,101). Among patients with ACS, the
default duration of dual antiplatelet therapy is
12 months, which may be shortened to 6 months in
case of high bleeding risk or extended to up to
30 months in case of low bleeding but high throm-
botic risk (100,101). Patients with RACD should
adhere to the same rigorous secondary prevention
strategies and lifestyle changes as patients without
RACD. After PCI, patients with RACD may be evalu-
ated within 3 months and on annual basis thereafter,
with noninvasive functional testing limited to
symptomatic patients or high-risk patients such as
those with left main disease.
TRANSCATHETER AORTIC
VALVE IMPLANTATION
INDICATION AND TREATMENT SELECTION. As
compared with patients without RACD, aortic valve
disease in patients with RACD is more frequently
associated with calcification of the ascending aorta,
involvement of coronary ostia, calcification of the
aortomitral curtain with extension into the anterior
FIGURE 8 A Patient With RACD Who Underwent TAVR
Echo showing severe aortic stenosis (A and B), no obstructive coronary disease (C to E, H, and I), and TAVR (F and G). Abbreviations as in Figures 3 and 5.
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923mitral leaflet, a higher prevalence of severe conduc-
tion abnormalities, and diastolic and/or systolic
dysfunction owing to myocardial fibrosis (46). All
these may potentially complicate transcatheter aortic
valve implantation (TAVR) owing to the risk of injury
to the ascending aorta or cerebral embolization (por-
celain aorta), coronary obstruction (ostial disease),
annulus rupture, pacemaker implantation, and low-
flow, low-gradient physiology, and require careful
pre-procedural planning.
TAVR for AS should be performed according to
guidelines (66,87). Currently, TAVR is recommended
in patients at increased surgical risk; but recent data
have suggested its superiority and noninferiority in
intermediate- and low-risk patients as compared with
surgery (102–104). TAVR should be considered the
default strategy among patients with RACD, particu-
larly if transfemoral access can be performed without
complicating factors such as advanced CAD, multi-
valvular disease, or an excessive risk for coronary
obstruction or annulus rupture (Figure 8).
OUTCOMES. Among patients included into the
PARTNER (Placement of Aortic Transcatheter Valve)
1B trial and continued access registry, 85 of 369 pa-
tients (23%) were considered inoperable for surgical
AVR based on technical ineligibility (105). The most
common criteria for surgical inoperability in these
patients were porcelain aorta (42%) and previousradiation therapy to the chest (25%). Patients
considered technically inoperable had a somewhat
shorter hospital stay versus those considered clini-
cally inoperable (5.3 vs. 5.9 days; p ¼ 0.04). Clinical
event rates among inoperable patients at 30 days
were 4.7% for all-cause mortality, 3.6% for stroke,
13% for hemorrhagic complications, and 17.6% for
vascular complications. At 2-year follow-up, mortal-
ity was lower among inoperable patients versus con-
servative treatment (23.3% vs. 67.4%; p < 0.001), and
increasing STS score was an independent predictor of
mortality, whereas technical inoperability was found
protective (105). A recent study reported outcomes of
98 patients with radiation-associated severe AS un-
dergoing TAVR (Figure 7) (84). Post-procedural per-
manent pacemaker was required in 15% of patients
and moderate to severe aortic regurgitation was
recorded in 8% of patients. At 2.3 years, the annual-
ized mortality was 8%/year, and multivariable anal-
ysis identified reduced LV stroke volume index as a
predictor of increased long-term mortality (84).
TECHNICAL CONSIDERATIONS. Compared with sur-
gery, TAVR performed via transfemoral access has
consistently been shown to provide similar or supe-
rior outcomes in terms of mortality and stroke, as well
as risk of renal failure, new-onset atrial fibrillation,
and major bleeding (106). As a result, transfemoral
access should be the default access in patients
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long as the vascular dimensions and anatomy
demonstrate feasibility. However, owing to chest ra-
diation exposure, transapical and transaortic access
require careful evaluation, and other alternative ac-
cess routes including transcaval, transaxillary, trans-
subclavian, and transcarotid may be explored. Precise
delineation of the topographic anatomy of the aortic
root by means of MDCT is routinely recommended in
patients considered for TAVR. Extension of calcium
into the ascending aorta and the aortomitral curtain
are associated with an increased risk of annular
rupture. This risk may be mitigated by avoiding pre-
dilation or consideration of self-expanding or me-
chanically expanding valves over balloon-expandable
valves. The use of newer-generation transcatheter
valves should minimize the risk of paravalvular
regurgitation. Patients with RACD also feature a
higher prevalence of AV conduction abnormalities,
which needs to be considered in device selection to
address the need of permanent pacemaker implan-
tation. Patients with porcelain aorta should also un-
dergo careful evaluation of atheromata of the
ascending aorta. The latter may be associated with
the risk of embolization during TAVR and may call for
cerebral embolic protection devices.
LONG-TERM FOLLOW-UP CARE. After discharge,
patients should be followed clinically, as well as by
serial transthoracic echocardiographic follow-up, at
1 month, 12 months, and then annually (66,87). Among
patients without indication for oral anticoagulation,
long-term antiplatelet therapy with either aspirin or
thienopyridine is recommended. Whether dual anti-
platelet therapy is necessary for a variable period of
time following TAVR is subject to debate.
OTHER TRANSCATHETER VALVE THERAPIES.
Because data on transcatheter mitral and tricuspid
valve therapies are evolving, there is not much
experience in the setting of RACD. However, mitral
annular calcification, commonly observed in RACD, is
associated with significantly increased mortality
following transcatheter mitral replacement (81,107).
Future refinements in technology shouldundoubtedly improve these data and increase feasi-
bility in challenging RACD patients. Additionally,
many patients present with paravalvular leaks
following initial valvular replacements. Management
decisions (especially cardiac reoperation [108] or
paravalvular leak closure) would have to be individ-
ualized in these high-risk patients; and the discussion
is beyond the scope of this article.
ELECTROPHYSIOLOGY
RACD-associated conduction abnormalities are
managed according to standard recommendations.
This may include antiarrhythmic agents, permanent
pacemakers or resynchronization therapy, and
implanted defibrillators for prevention of sudden
cardiac death.
CONCLUSIONS
With increased awareness, incidence of RACD from
prior XRT exposure is likely to rise over the next
decade. Management of RACD remains challenging
due to increased rates of morbidity and mortality.
Coordinated management by an experienced team of
providers at a center of excellence is strongly advo-
cated. Timing of surgical intervention must be indi-
vidualized on the basis of the complexity of the
disease, comorbidities, and technical difficulty.
Percutaneous options are increasingly available,
although their use and suitability in RACD is
evolving. It is crucial to develop comprehensive
multimodality imaging based screening protocols to
adequately identify those at risk, plan interventions,
and evaluate treatment response. However, the
longer-term future should involve developing XRT
delivery protocols that minimize the chances of
developing RACD in the future.
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